Novartis announced the acquisition of Selexys Pharmaceuticals; the deal comes as a consequence of the positive results obtained during the SUSTAIN study, a phase 2 trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). This hereditary blood disorder is characterized by sickle-shaped red blood cells and it represents a life-long disease with many forms that can range in clinical severity from asymptomatic to life-threatening. “Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease,” said Bruno Strigini, CEO of Novartis Oncology.

Bruno Strigini, CEO NovartisOncology
Bruno Strigini, CEO NovartisOncology

“With this acquisition, Novartis is able to leverage its leadership in haematology research to advance development of a potential new treatment option for patients living with this debilitating condition.” Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.


Please enter your comment!
Please enter your name here